Service d'ORL et Chirurgie maxillo-faciale, Centre Hospitalier Universitaire de Nîmes, Place du Pr. Robert Debre, 30029 Nîmes Cedex 9, France.
Head Neck. 2010 Dec;32(12):1712-9. doi: 10.1002/hed.21491.
To date, more than 60 gene expression profiling (GEP) studies have been published in the field of head and neck squamous cell carcinoma (HNSCC) with variable objectives, methods, and results.
The purpose of this study was to present a state-of-the-art review of GEP in HNSCC focusing on the current advances and perspectives for clinical applications.
Gene expression signatures have been developed to identify screening and diagnostic molecular markers, to improve tumor staging (cervical lymph node and distant metastasis prediction), to differentiate lung metastasis of HNSCC from primary lung squamous cell carcinoma, to predict tumor response to chemoradiotherapy, and to provide outcome predictors.
Some transcriptional signatures that could improve HNSCC management have been identified, but further analyses are required to properly validate and to precisely evaluate their clinical relevance. After an exploratory phase, the completion of large scale projects with stringent methodology is now necessary to transfer GEP from bench to bedside.
迄今为止，已有超过 60 项关于头颈部鳞状细胞癌（HNSCC）的基因表达谱（GEP）研究发表，其目的、方法和结果各不相同。
本研究旨在对头颈部鳞状细胞癌的 GEP 进行综述，重点介绍其在临床应用方面的最新进展和前景。
已经开发出基因表达谱来识别筛选和诊断分子标志物，以改善肿瘤分期（颈淋巴结和远处转移预测），区分头颈部鳞状细胞癌的肺转移与原发性肺鳞状细胞癌，预测肿瘤对放化疗的反应，并提供预后预测指标。
已经确定了一些可能改善头颈部鳞状细胞癌管理的转录组特征，但需要进一步分析以正确验证和准确评估其临床相关性。在探索阶段之后，现在需要完成具有严格方法学的大型项目，将 GEP 从实验室转移到临床。
